These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 32240796)

  • 1. Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial.
    Schuler M; Berardi R; Lim WT; de Jonge M; Bauer TM; Azaro A; Gottfried M; Han JY; Lee DH; Wollner M; Hong DS; Vogel A; Delmonte A; Akimov M; Ghebremariam S; Cui X; Nwana N; Giovannini M; Kim TM
    Ann Oncol; 2020 Jun; 31(6):789-797. PubMed ID: 32240796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification.
    Choi W; Park SY; Lee Y; Lim KY; Park M; Lee GK; Han JY
    Cancer Res Treat; 2021 Oct; 53(4):1024-1032. PubMed ID: 33540494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial.
    Wolf J; Hochmair M; Han JY; Reguart N; Souquet PJ; Smit EF; Orlov SV; Vansteenkiste J; Nishio M; de Jonge M; Akerley W; Garon EB; Groen HJM; Tan DSW; Seto T; Frampton GM; Robeva A; Carbini M; Le Mouhaer S; Yovine A; Boran A; Bossen C; Yang Y; Ji L; Fairchild L; Heist RS
    Lancet Oncol; 2024 Oct; 25(10):1357-1370. PubMed ID: 39362249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capmatinib in
    Wolf J; Seto T; Han JY; Reguart N; Garon EB; Groen HJM; Tan DSW; Hida T; de Jonge M; Orlov SV; Smit EF; Souquet PJ; Vansteenkiste J; Hochmair M; Felip E; Nishio M; Thomas M; Ohashi K; Toyozawa R; Overbeck TR; de Marinis F; Kim TM; Laack E; Robeva A; Le Mouhaer S; Waldron-Lynch M; Sankaran B; Balbin OA; Cui X; Giovannini M; Akimov M; Heist RS;
    N Engl J Med; 2020 Sep; 383(10):944-957. PubMed ID: 32877583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancer.
    Felip E; Metro G; Tan DSW; Wolf J; Mark M; Boyer M; Hughes BGM; Bearz A; Moro-Sibilot D; Le X; Puente J; Massuti B; Tiedt R; Wang Y; Xu C; Mardjuadi FI; Cobo M
    Lung Cancer; 2024 Jun; 192():107820. PubMed ID: 38763104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
    Wu YL; Smit EF; Bauer TM
    Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.
    Wu YL; Zhang L; Kim DW; Liu X; Lee DH; Yang JC; Ahn MJ; Vansteenkiste JF; Su WC; Felip E; Chia V; Glaser S; Pultar P; Zhao S; Peng B; Akimov M; Tan DSW
    J Clin Oncol; 2018 Nov; 36(31):3101-3109. PubMed ID: 30156984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database.
    Reale ML; Passiglia F; Cappuzzo F; Minuti G; Occhipinti M; Bulotta A; Delmonte A; Sini C; Galetta D; Roca E; Pelizzari G; Cortinovis D; Gariazzo E; Pilotto S; Citarella F; Bria E; Muscolino P; Pozzessere D; Carta A; Pignataro D; Calvetti L; Leone F; Banini M; Di Micco C; Baldini E; Favaretto A; Malapelle U; Novello S; Pasello G; Tiseo M
    ESMO Open; 2024 Sep; 9(9):103680. PubMed ID: 39214048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study.
    Ferreira M; Swalduz A; Greillier L; du Rusquec P; Curcio H; Raimbourg J; Toffart AC; Gounant V; Couraud S; De Chabot G; Friard S; Hureaux J; Jeannin G; Odier L; Ricordel C; Wislez M; Descarpentries C; Herbreteau G; Missy P; Morin F; Westeel V; Cortot AB
    Lung Cancer; 2024 Oct; 196():107934. PubMed ID: 39277916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts.
    Bang YJ; Su WC; Schuler M; Nam DH; Lim WT; Bauer TM; Azaro A; Poon RTP; Hong D; Lin CC; Akimov M; Ghebremariam S; Zhao S; Giovannini M; Ma B
    Cancer Sci; 2020 Feb; 111(2):536-547. PubMed ID: 31778267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET-amplified advanced NSCLC: GEOMETRY mono-1 study.
    Seto T; Ohashi K; Sugawara S; Nishio M; Takeda M; Aoe K; Moizumi S; Nomura S; Tajima T; Hida T
    Cancer Sci; 2021 Apr; 112(4):1556-1566. PubMed ID: 33506571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study.
    Furqan M; Karanth S; Goyal RK; Cai B; Rombi J; Davis KL; Caro N; Saliba T
    Future Oncol; 2024; 20(22):1553-1563. PubMed ID: 38629593
    [No Abstract]   [Full Text] [Related]  

  • 13. Interstitial lung disease associated with capmatinib therapy in a patient with non-small cell lung cancer harboring a skipping mutation of MET exon 14.
    Kanemura H; Takeda M; Shimizu S; Nakagawa K
    Thorac Cancer; 2021 Feb; 12(4):549-552. PubMed ID: 33347701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations.
    Kron A; Scheffler M; Wiesweg M; Hummel HD; Kulhavy J; Gatteloehner S; Kollmeier J; Schubart C; Groß T; Demes MC; Keymel S; Joosten M; Merkelbach-Bruse S; Wölwer CB; Tufman A; Kauffmann-Guerrero D; Oeser K; Zehaczek M; Jeratsch U; Wolf J
    Eur J Cancer; 2024 Aug; 207():114158. PubMed ID: 38941869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors.
    Moreno V; Greil R; Yachnin J; Majem M; Wermke M; Arkenau HT; Basque JR; Nidamarthy PK; Kapoor S; Cui X; Giovannini M
    Clin Ther; 2021 Jun; 43(6):1092-1111. PubMed ID: 34053700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor.
    Dagogo-Jack I; Moonsamy P; Gainor JF; Lennerz JK; Piotrowska Z; Lin JJ; Lennes IT; Sequist LV; Shaw AT; Goodwin K; Stevens SE; Do A; Digumarthy SR; Price K; Muzikansky A; Hata AN; Heist RS
    J Thorac Oncol; 2021 May; 16(5):850-859. PubMed ID: 33545388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
    Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
    Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capmatinib for the treatment of non-small cell lung cancer.
    Vansteenkiste JF; Van De Kerkhove C; Wauters E; Van Mol P
    Expert Rev Anticancer Ther; 2019 Aug; 19(8):659-671. PubMed ID: 31368815
    [No Abstract]   [Full Text] [Related]  

  • 19. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.
    Fujino T; Suda K; Koga T; Hamada A; Ohara S; Chiba M; Shimoji M; Takemoto T; Soh J; Mitsudomi T
    J Hematol Oncol; 2022 Jun; 15(1):79. PubMed ID: 35690785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capmatinib for non-small cell lung cancer.
    Alzofon N; Jimeno A
    Drugs Today (Barc); 2021 Jan; 57(1):17-25. PubMed ID: 33594387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.